GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cyclerion Therapeutics Inc (NAS:CYCN) » Definitions » Price-to-Free-Cash-Flow

Cyclerion Therapeutics (Cyclerion Therapeutics) Price-to-Free-Cash-Flow

: N/A (As of Today)
View and export this data going back to 2019. Start your Free Trial

As of today (2024-04-16), Cyclerion Therapeutics's share price is $3.32. Cyclerion Therapeutics's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $-8.85. Hence, Cyclerion Therapeutics's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for Cyclerion Therapeutics's Price-to-Free-Cash-Flow or its related term are showing as below:

CYCN's Price-to-Free-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 31.34
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

Cyclerion Therapeutics's Free Cash Flow per Share for the three months ended in Dec. 2023 was $-0.63. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $-8.85.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 42.90% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 36.30% per year.

During the past 7 years, Cyclerion Therapeutics's highest 3-Year average Free Cash Flow per Share Growth Rate was 42.90% per year. The lowest was 7.00% per year. And the median was 37.55% per year.


Cyclerion Therapeutics Price-to-Free-Cash-Flow Historical Data

The historical data trend for Cyclerion Therapeutics's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cyclerion Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Free-Cash-Flow
Premium Member Only Premium Member Only - - - - -

Cyclerion Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Free-Cash-Flow Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison

For the Biotechnology subindustry, Cyclerion Therapeutics's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cyclerion Therapeutics Price-to-Free-Cash-Flow Distribution

For the Biotechnology industry and Healthcare sector, Cyclerion Therapeutics's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Cyclerion Therapeutics's Price-to-Free-Cash-Flow falls into.



Cyclerion Therapeutics Price-to-Free-Cash-Flow Calculation

Cyclerion Therapeutics's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=3.32/-8.845
=N/A

Cyclerion Therapeutics's Share Price of today is $3.32.
Cyclerion Therapeutics's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-8.85.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Cyclerion Therapeutics  (NAS:CYCN) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Cyclerion Therapeutics Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Cyclerion Therapeutics's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Cyclerion Therapeutics (Cyclerion Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
245 First Street, 18th Floor, Cambridge, MA, USA, 02142
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.
Executives
Terrance Mcguire director C/O POLARIS VENTURE PARTNERS LP, 1000 WINTER STREET, SUITE 3350, WALTHAM MA 02154
Steven Hyman director C/O VOYAGER THERAPEUTICS, INC., 75 SIDNEY STREET, CAMBRIDGE MA 02139
Andreas Busch officer: Chief Scientific Officer C/O CYCLERION THERAPEUTICS, INC., 301 BINNEY STREET, CAMBRIDGE MA 02142
George H Conrades director 500 TECHNOLOGY SQUARE, FIFTH FLOOR, CAMBRIDGE MA 02139
Stephanie Lovell director C/O CYCLERION THERAPEUTICS, INC., 301 BINNEY STREET, CAMBRIDGE MA 02142
Ole Isacson director CYCLERION THERAPEUTICS, INC., 301 BINNEY STREET, CAMBRIDGE MA 02142
Kevin Churchwell director C/O CYCLERION THERAPEUTICS, CAMBRIDGE MA 02142
Michael Mendelsohn director C/O CYCLERION THERAPEUTICS, INC., 301 BINNEY STREET, CAMBRIDGE MA 02142
Peter M Hecht director, officer: Chief Executive Officer C/O CYCLERION THERAPEUTICS, INC., 301 BINNEY STREET, CAMBRIDGE MA 02142
Slate Path Capital Lp 10 percent owner 717 5TH AVENUE, 16TH FL., NEW YORK NY 10022
Errol B Desouza director 215 COLLEGE ROAD, PARAMUS NJ 07652
Anjeza Gjino officer: Chief Financial Officer C/O CYCLERION THERAPEUTICS, INC., 245 FIRST STREET, 18TH FLOOR, CAMBRIDGE MA 02142
Christopher I Wright officer: Chief Medical Officer C/O CYCLERION THERAPEUTICS, INC., 245 FIRST STREET, 18TH FLOOR, CAMBRIDGE MA 02142
Cheryl Gault officer: Chief Operating Officer CYCLERION THERAPEUTICS, INC., 245 FIRST STREET, 18TH FLOOR, CAMBRIDGE MA 02142
Mark G Currie officer: President and CSO C/O CYCLERION THERAPEUTICS, INC., 301 BINNEY STREET, CAMBRIDGE MA 02142

Cyclerion Therapeutics (Cyclerion Therapeutics) Headlines

From GuruFocus

Cyclerion Announces CY6463 Clinical Pipeline and Corporate Updates

By GuruFocusNews GuruFocusNews 02-24-2022

Cyclerion Announces Reverse Stock Split

By sperokesalga sperokesalga 05-15-2023